53 results
Page of 5
  • ACCL1333

    A study designed to evaluate the safety and efficacy of Apixaban for Thromboembolism Prevention versus No Systemic Anticoagulant Prophylaxis during Induction Chemotherapy in children with newly diagnosed Acute Lympho.

    Type: Treatment

    Principal Investigator: Richard Drachtman, MD

    Trial is open for enrollment

    For inquiries, call (732) 235-8861
    • Rutgers Robert Wood Johnson Medical School
    • Robert Wood Johnson University Hospital
  • AEGIS II

    A phase 3, multi-center, double-blind, randomized, placebo-controlled, parallel-group study designed to investigate the efficacy and safety of CSL 112 (Apolipoprotein A-I: human) on reducing the risk of major adverse CV events in subjects with acute coronary syndrome (ACS) diagnosed with either ST-segment elevation myocardial infarction (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI), including those managed with percutaneous coronary intervention (PCI) or medically managed.

    Type: Treatment

    Trial is open for enrollment

    View All Details
    • Principal Investigator:
      Sharan Mahal, MD

    For inquiries, call (908) 864-4027
    • RWJ University Hospital Somerset
  • ALIGN-AR

    To evaluate the safety and effectiveness/performance of the Transfemoral JenaValve Pericardial TAVR System in the treatment of patients with symptomatic severe aortic regurgitation.

    Type: Device trial

    Principal Investigator: Mark Russo, MD

    Trial is open for enrollment

    For inquiries, call (732) 235-9215
    • Rutgers Robert Wood Johnson Medical School
    • Robert Wood Johnson University Hospital
  • ALLIANCE

    To establish the safety and effectiveness of the Edwards SAPIEN X4 Transcatheter Heart Valve (THV) in subjects with symptomatic, severe, calcific aortic stenosis (AS).

    Type: Device Trial

    Principal Investigator: Mark Russo, MD

    Trial is open for enrollment

    For inquiries, call (732) 235-9215
    • Rutgers Robert Wood Johnson Medical School
    • Robert Wood Johnson University Hospital
  • ALLIANCE VIV

    To establish the safety and effectiveness of the Edwards SAPIEN X4 Transcatheter Heart Valve (THV) in subjects who are at high or greater surgical risk with a failing aortic bioprosthetic valve.

    Type: Device Trial

    Principal Investigator: Mark Russo, MD

    Trial is open for enrollment

    For inquiries, call (732) 235-9215
    • Rutgers Robert Wood Johnson Medical School
    • Robert Wood Johnson University Hospital
  • AMPLATZER™ Amulet™ Left Atrial Appendage Occluder Randomized Controlled Trial

    A study designed to evaluate the safety and effectiveness of the AMPLATZER Amulet Left Atrial Appendage Occluder.

    Trial is open for enrollment

    View All Details
    • Principal Investigator:
      Dobesh, David M.D.

    For inquiries, call (973) 736-6333
    • Cooperman Barnabas Medical Center
  • ARRAY 797-301

    A phase 3, multinational, randomized, placebo-controlled study of ARRY-371797 in patients with symptomatic dilated cardiomyopathy due to a lamin A/C gene mutation.

    Type: Drug trial

    Principal Investigator: Saurabh Kapoor, MD

    Trial is open for enrollment

    For inquiries, call (973) 926-8451
    • Newark Beth Israel Medical Center
  • Assessing the Normal Microbiome and Virome of the Lung: A Pilot Study

    Trial is open for enrollment.

    View All Details
    • Principal Investigator:
      Subroto Paul M.D.

    For inquiries, call (973) 322-2224
    • Cooperman Barnabas Medical Center
  • Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral Anticoagulation (ASAP-TOO)

    Trial is open for enrollment.

    View All Details
    • Principal Investigator:
      Dobesh, David M.D.

    For inquiries, call (973) 736-6333
    • Cooperman Barnabas Medical Center
  • ATRIUM

    AbatacepT foR ImmUne checkpoint inhibitor associated Myocarditis (ATRIUM): A Phase 3, Investigator-Initiated, Randomized, DoubleBlind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Compared to Placebo in Hospitalized Participants with Immune Checkpoint Inhibitor Associated Myocarditis

    To qualify, participants must:

    • Be of 18 years and older
    • Recent use of an FDA-approved immune checkpoint inhibitor alone or in combination with other cancer therapies (i.e., chemotherapy, radiation therapy or targeted therapy)
    • A diagnosis of myocarditis
    • Must be hospitalized at the time of randomization
    • On 1000 mg of solumedrol per day for myocarditis or with an intent to initiate 1000 mg of solumedrol per day for myocarditis within 24 hours of first administration of study drug
    • Serum evidence of ongoing myocardial injury

    Principal Investigator: Dr. Sasha East

    Study Sponsor:Massachusetts General Hospital

    Trial is open for enrollment

    For inquiries, call (732) 867-1550 or email: cardiologyclinicaltrials@rwjms.rutgers.edu

    • Rutgers Robert Wood Johnson Medical School
    • Robert Wood Johnson University Hospital
  • Biofourmis

    Artificial Intelligence Mobile Health Trial of A Digital Platform To Optimize GDMT Using Wearable Sensors

    Guideline directed medical treatment (GDMT) has shown to improve outcomes in patients with heart failure with reduced ejection fraction (HFrEF). The Division of Cardiovascular Disease and Hypertension is seeking patients with HFrEF for a multicenter, randomized, outpatient study to evaluate the effectiveness of the cloud based BiovitalsHF™ technology. The study provides a remote wireless vital collection device and involves wearing a wearable sensor (Everion®) on the arm that will be remotely monitored for 90 days. The BiovitalsHF™ platform integrates data collected remotely from the vital collection device and the wearable sensor to manage the initiation and titration of GDMT outside of traditional clinical encounters.

    To qualify, participants must:

    • Be at least 22 years old
    • Have been diagnosed with heart failure for at least 3 months
    • Have an ejection fraction less than or equal to 40%

    This study offers Continuous vital signs trends, Remote medication management and Care coordination

    Principal Investigator: Dr. Partho P. Sengupta

    Study Sponsor: Biofourmis Inc. (www.biofourmis.com)

    Trial is closed for enrollment

    For inquiries, call (732) 867-1550 or email: cardiologyclinicaltrials@rwjms.rutgers.edu

    • Rutgers Robert Wood Johnson Medical School
    • Robert Wood Johnson University Hospital
  • BiSpectral Index (BIS) Monitoring and Sedation Practices in Critically Ill Mechanically Ventilated Patients: A Single Center, Prospective, Randomized Control Trial

    Trial is open for enrollment

    View All Details
    • Principal Investigator:
      Nirav Mistry M.D.

    For inquiries, call (973) 322-2224
    • Cooperman Barnabas Medical Center
Page of 5